Ionara Bio

About

Funding history · 2 rounds · $800K total

Q&A

What is Ionara Bio's primary focus?

Ionara Bio is developing novel, proprietary small molecules that target and block the TRPV2 channel, which is a key driver of inflammatory responses that impair cardiac structure and function following acute myocardial infarction (AMI).

What is the goal of Ionara Bio's lead candidate?

The company’s lead candidate, a first-in-class TRPV2 inhibitor, is designed to improve cardiac function and reduce pathological cardiac fibrosis, aiming for significantly enhanced post-AMI recovery.

When was Ionara Bio founded?

Ionara Bio was founded in May 2024.

Where is Ionara Bio headquartered?

Ionara Bio is headquartered in Ness Ziona, Israel.

What is Ionara Bio's current employee count?

Ionara Bio has 3 employees, falling within the 1-10 employee bucket.

What is Ionara Bio's total funding raised to date?

Ionara Bio has raised a total of $800,000 USD.

When did Ionara Bio complete its most recent funding round?

Ionara Bio completed a Seed funding round in January 2026, raising $800,000 USD.

Which investor participated in Ionara Bio's January 2026 Seed round?

Peregrine Ventures participated in Ionara Bio's Seed funding round in January 2026.

Who is the CEO of Ionara Bio?

Nili Schutz is the CEO of Ionara Bio.

Team · 1

Nili Schutz

CEO

LinkedIn ↗

Sectors & technology

Tags